Contact Us
Drug Search Results
More Filters [+]

Raclopride

Alternative Names: raclopride, meglitinides
Latest Update: 2024-10-14
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: D2 Antagonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral,Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: AstraZeneca
Company Location: CAMBRIDGE X0 CB2 0AA
Company CEO: Pascal Soriot
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Raclopride

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 4: Bulimia Nervosa|Anorexia|Malnutrition|Substance Abuse Unspecified

Phase 2: Healthy Volunteers|Parkinson's Disease

Phase 1: Opioid-Related Disorders|Depressive Disorder|Obesity|Overweight|Traumatic Brain Injury

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
17-AA-0114

P1

Recruiting

Opioid-Related Disorders

2025-12-31

NCT03999190

N/A

Withdrawn

Schizophrenia

2025-07-01

14-N-0083

P1

Completed

Traumatic Brain Injury

2024-02-13

18-DK-0132

P1

Completed

Overweight|Obesity

2022-03-31

Recent News Events

Date

Type

Title

07/01/2024

PubMed

 Effects of deep brain stimulation on dopamine D2 receptor binding in patients with treatment-refractory depression.

10/03/2024

News Article

 TheracosBio Partners with PBA Health to Provide Affordably Priced FDA-approved Diabetes Medication to Thousands of Independent Community Pharmacies

08/28/2024

News Article

 Release of Negotiated Prices Under Inflation Reduction Act Reveals that BRENZAVVY® (bexagliflozin) Remains the Lowest Priced SGLT2 Inhibitor

06/05/2024

News Article

 Rising Obesity and Inactivity Drive Global Obesity-Diabetes Drug Market to USD 97,567.4 Million by 2034, with North America Leading Due to High Obesity Rates

05/11/2024

PubMed

 Seasonal variation in D2/3 dopamine receptor availability in the human brain.

05/04/2024

PubMed

 Dopamine, activation of ingestion and evaluation of response efficacy: a focus on the within-session time-course of licking burst number.

04/12/2024

News Article

 Head-to-Head Study Finds TheracosBio's BRENZAVVY® (bexagliflozin) Non-Inferior to Dapagliflozin in Chinese Patients With Type 2 Diabetes

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions